Uso de insulinas en el tratamiento de la Diabetes Mellitus tipo 1 y 2

Pablo Kuri Morales; Carlos Álvarez Lucas; Fernando Lavalle González; Antonio González Chávez; José de Jesús Ríos González; David González Bárcena; Joel Rodríguez Saldaña; Juan Rosas Guzmán; Sergio Zúñiga Guajardo; Sara Arellano Montaño; Javier Sánchez Guerrero; Juan Antonio Torres; Armando Villegas; Ismael Javier Chavira López; Carlos Herrera Madrigal; Isidro Roberto Camacho Beiza; Evangelina Valdés Guerrero; Patricia Pérez Sánchez; Margarita Torres Tamayo; Joel Rodríguez Sierra; Agustín Lara Esqueda; Martha Yolanda Martínez M; Hugo Laviada Molina; Rogelio Zacarías Castillo; Emmanuel Martínez Lara; Sergio Islas A; Rodrigo Suárez Otero; Rutila Castañeda Limones; Jaime Camacho Aguilera; Manuel González Ortiz; Rafael Violante Ortíz; Mario Arceo Guzmán; Esperanza Martínez; Guillermo Fanghänel Salmón

2007, Número 2

Rev Endocrinol Nutr 2007; 15 (2)

Uso de insulinas en el tratamiento de la Diabetes Mellitus tipo 1 y 2

Kuri MP, Álvarez LC, Lavalle GF, González CA, Ríos GJJ, González BD, Rodríguez SJ, Rosas GJ, Zúñiga GS, Arellano MS, Sánchez GJ, Antonio TJ, Villegas A, Chavira LIJ, Herrera MC, Camacho BIR, Valdés GE, Pérez SP, Torres TM, Rodríguez SJ, Lara EA, Martínez MMY, Laviada MH, Zacarías CR, Martínez LE, Islas AS, Suárez OR, Castañeda LR, Camacho AJ, González OM, Violante OR, Arceo GM, Martínez E, Fanghänel SG

Texto completo

Cómo citar este artículo

Idioma: Español
Referencias bibliográficas: 76
Paginas: 75-103
Archivo PDF: 710.03 Kb.

FRAGMENTO

1) Generalidades

Fisiología de los islotes pancreáticos y cambios de la secreción de insulina en la diabetes

La insulina, polipéptido producido y secretado por las células beta del páncreas, es una hormona esencial para el crecimiento somático y desarrollo motriz; desempeña un papel muy importante en la regulación del metabolismo de carbohidratos, grasas y proteínas. Se sintetiza a partir de una prehormona de 81 residuos de aminoácidos que se denomina proinsulina (Figura 1).

REFERENCIAS (EN ESTE ARTÍCULO)

Adler AI, Stevens RJ, Neil A, Stratton IM, Boulton AJ, Holman RR. UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diabetes Care 2002; 25: 894-9.
Adlersberg MA, Fernando S, Spollett GR, Inzucchi SE. Glargine and Lispro: Two cases of mistaken identity. Diabetes Care 2002; 25: 404-5.
Ahmann AJ, Riddle MC. Current oral agents for type 2 diabetes. Many options, but which to choose when? Postgrad Med 2002; 111(5): 32-4, 37-40, 43-6.
Ahmann AJ, Riddle MC. What to do when two oral agents fail to control type 2 diabetes a matter of opinion or a matter of fact? Am J Med 2004; 116(4): 276-8.
Bellary S, Barnett AH. Inhaled insulin: new technology, new possibilities. Int J Clin Pract 2006; 60(6): 728-34.
Bott U, Ebrahim S, Hirschberger S, Skovlund SE. Effect of the rapid-acting insulin analogue insulin aspart on quality of life and treatment satisfaction in patients with Type 1 diabetes. Diabet Med 2003; 20(8): 626-34.
Braunstein SN, White JR. Trends in the management of type 2 diabetes: an emerging role for insulin. J Manag Care Pharm 2005; 11(1 Suppl B): S2-11; quiz S12-3.
Brunner GA, Hirschberger S, Sendlhofer G et. al. Post-prandial administration of the insulin analogue insulin aspart in patients with Type 1 diabetes mellitus Diabet Med 2000; 17(5): 371-5.
Brunton SA, White JR Jr, Renda SM. The role of basal insulin in type 2 diabetes management. J Fam Pract 2005; Suppl: S1-8.
Cefalu WT. Evolving strategies for insulin delivery and therapy. Drugs 2004; 64(11): 1149-61.
Chantelau E. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin. Diabetes Care 2006; 29(2): 477.
Danne T, Aman J, Schober E, Deiss D, Jacobsen JL, Friberg HH, Jensen LH; ANA 1200 Study Group. A comparison of postprandial and preprandial administration of insulin aspart in children and adolescents with type 1 diabetes. Diabetes Care 2003; 26(8): 2359-64.
Davies M, Storms F, Shutler S, Bianchi-Biscay M, Gomis R. LANTUS Study Group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282-1288.
Davis TM, Cull CA, Holman RR. Relationship between ethnicity and glycemic control, lipid profiles, and blood pressure during the first 9 years of type 2 diabetes: U.K. Prospective diabetes study (UKPDS 55). Diabetes Care 2001; 24: 11671174.
De Fronzo RA, Bergenstal RM, Cefalu WT, Pullman J, Lerman S, Bode BW, Phillips LS. Exubera Phase III Study Group. Efficacy of inhaled insulin in patients with type 2 diabetes not controlled with diet and exercise: A 12-week, randomized, comparative trial. Diabetes Care 2005; 28: 1922-1928.
DeVries JH, Lindholm A, Jacobsen JL, Heine RJ, Home PD. Tri-Continental Insulin Aspart Study Group. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes. Diabet Med 2003; 20(4): 312-8.
DeWitt DE, Dugdale DC. Using new insulin strategies in the outpatient treatment of diabetes. JAMA 2003; 289(17): 2265-9.
DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. JAMA 2003; 289: 2254-64.
Diagnosis and classification of diabetes mellitus. American Diabetes Association. Diabetes Care 2007 30: S42-47.
Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the diabetes control and complications trial. A randomized, controlled trial. The diabetes control and complications trial research group. Ann Intern Med 1998; 128(7): 517-23.
Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The diabetes control and complications trial research group. Diabetes Care 2000; 23(8): 1084-91.
Fineberg SE, Kawabata T, Finco-Kent D, Liu C, Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005; 90(6): 3287-94.
Hamann A, Matthaei S, Rosak C, Silvestre L. A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes. Diabetes Care 2003; 26: 1738-1744.
Heine RJ. Unlocking the opportunity of tight glycaemic control. Promise ahead: the role of inhaled insulin in clinical practice. Diabetes Obes Metab 2005; 7 Suppl 1: S19-23.
Heise T, Bott S, Tusek C, Stephan JA, Kawabata T, Finco-Kent D, Liu C, Krasner A. The effect of insulin antibodies on the metabolic action of inhaled and subcutaneous insulin: a prospective randomized pharmacodynamic study. Diabetes Care 2005; 28(9): 2161-9.
Herbst KL, Hirsch IB. Insulin strategies for primary care providers. Clinical Diabetes 2002; 20:11-17.
Hermansen K, Colombo M, Storgaard H, Ostergaard A, Kolendorf K, Madsbad S. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes. Diabetes Care 2002; 25(5): 883-8.
Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr. et al. A real-world approach to insulin therapy in primary care practice. Clinical Diabetes 2005; 23: 78-86.
Hirsch IB. Treatment of patients with severe insulin deficiency; what we have learned over the past 2 years. Am J Med 2004; 116 Suppl 3A: 17S-22S.
Hollander PA, Blonde L, Rowe R, Mehta AE, Milburn JL, Hershon KS, Chiasson JL, Levin SR. Efficacy and safety of inhaled insulin (exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomized, comparative trial. Diabetes Care 2004; 27(10): 2356-62.
Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K. Prospective Diabetes Study 44). Diabetes Care 1999: 22: 960-4.
Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin aspart study group. Diabetes Care 1998; 21(11): 1904-9.
Home PD, Lindholm A, Riis A. European insulin aspart study group. Insulin aspart vs human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 2000; 17(11): 762-70.
Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28(2): 254-9.
Lebovitz HE, Austin MM, Blonde L, Davidson JA, Del Prato S, Gavin JR 3rd, Handelsman Y, Jellinger PS, Levy P, Riddle MC, Roberts VL, Siminerio LM. ACE/AACE Diabetes recommendations implementation writing committee. ACE/AACE consensus conference on the implementation of outpatient management of diabetes mellitus: consensus conference recommendations. Endocr Pract 2006; 12 Suppl 1: 6-12.
Leiter LA. Should you put all diabetic patients on statins? J Fam Pract 2007; 56(4): 294-300.
LeRoith D, Levetan CS, Hirsch IB, Riddle MC. Type 2 diabetes: the role of basal insulin therapy. J Fam Pract 2004; 53(3): 215-22.
Manual para el Manejo de las Insulinas 2004. Centro Nacional de Vigilancia Epidemiológica y Control de Enfermedades. Secretaría de Salud. México, 2004.
Norma Oficial Mexicana. NOM-015-SSA2-1994. Adendum. Uso de combinaciones en el tratamiento de la Diabetes Mellitus tipo 2. Secretaría de Salud, México, 2003.
Norma Oficial Mexicana NOM-015-SSA2-1994, para la prevención tratamiento y control de la diabetes. Secretaría de Salud. México. 2001.
Norma Oficial Mexicana. NOM-015-SSA2-1994. Proyecto de Modificación. Uso de insulinas en el tratamiento de la diabetes mellitus tipo 1 y 2. Secretaría de Salud. México, 2005.
Odegard PS, Capoccia KL. Inhaled insulin: Exubera. Ann Pharmacother 2005; 39(5): 843-53.
Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001; 358(9283): 739-46.
Patton JS, Bukar JG, Eldon MA. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 2004; 43(12): 781-801.
Pettitt DJ, Ospina P, Kolaczynski JW, Jovanovic L. Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care. 2003; 26(1): 183-6.
Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006; 28(10): 1569-81.
Plank J, Wutte A, Brunner G, Siebenhofer A et al. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes. Diabetes Care 2002; 25(11): 2053-7.
Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A; INITIATE Study Group. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28(2): 260-5.
Rave K, Bott S, Heinemann L, Sha S, Becker RH, Willavize SA, Heise T. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005; 28(5): 1077-82.
Riddle MC, Karl DM. Insulin treatment for type 2 diabetes. JAMA 1998; 279(19): 1523.
Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26(11): 3080-6.
Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin North Am 2005; 34(1): 77-98.
53 Riddle MC. Is initial combination therapy effective in the treatment of type 2 diabetes? Nat Clin Pract Endocrinol Metab 2006; 2(5): 254-5.
Riddle MC. Making the transition from oral to insulin therapy. Am J Med 2005; 118 Suppl 5A: 14S-20S.
Riddle MC. The treat-to-target trial and related studies. Endocr Pract 2006; 12 Suppl 1: 71-9.
Riddle MC. The underuse of insulin therapy in North America. Diabetes Metab Res Rev 2002; 18 Suppl 3: S42-9.
Riddle MC. Timely initiation of basal insulin. Am J Med 2004; 116 Suppl 3A: 3S-9S.
Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care 2004; 27(6): 1318-23.
Rosenstock J, Dailey G, Massi-Benedetti M, Fritsche A, Lin Z, Salzman A. Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-955.
Rosenstock J, Zinman B, Murphy LJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan SP, Cefalu WT. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2005; 143(8): 549-58.
Rosenstock J. Basal insulin supplementation in type 2 diabetes; refining the tactics. Am J Med 2004; 116 Suppl 3A: 10S-16S.
Royle P, Waugh N, McAuley L, McIntyre L, Thomas S. Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev 2004; (3): CD003890. Review.
Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 2004; 27(10): 2495-7.
Scherbaum WA. Unlocking the opportunity of tight glycaemic control. Inhaled insulin: clinical efficacy. Diabetes Obes Metab 2005; 7 Suppl 1: S9-13.
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23(2): B21-9.
Skyler JS, Jovanovic L, Klioze S, Reis J, Duggan W. Two-year safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 1 diabetes. Inhaled Human Insulin Type 1 Diabetes Study Group. Diabetes Care 2007; 30(3): 579-85.
Skyler JS, Weinstock RS, Raskin P, Yale JF, Barrett E, Gerich JE, Gerstein HC. Inhaled insulin phase iii type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial. Diabetes Care 2005; 28(7): 1630-5.
Standards of Medical Care in Diabetes 2007. American Diabetes Association. Diabetes Care 2007; 30: S4-41.
Standards of Medical Care in Diabetes. Diabetes Care 2006; 29: S4-S42.
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14): 977-86.
Turner R, Cull CA, Holman RR. UKPDS 17: a 9 year update of randomized, controlled trial of the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996; 124: 136-45.
Weiss SR, Cheng SL, Kourides IA, Gelfand RA, Landschulz WH. Inhaled insulin phase II study group. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents: a randomized controlled trial. Arch Intern Med 2003; 163(19): 2277-82.
White JR Jr. Insulin glargine clinical trials. Clin Ther 2004; 26(7): 1179-81.
White JR Jr., Davis SN, Cooppan R, Davidson MB et al. Clarifying the role of insulin in type 2 diabetes management. Clin Diabetes 2003 21: 14-21.
Wright A, Burden F, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective diabetes study (UKPDS 57) Diabetes Care 2002; 25: 330-6.
Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992; 327(20): 1426-1433.